Your session is about to expire
← Back to Search
Subcutaneous vs Intravenous Atezolizumab for Lung Cancer
Study Summary
This trial will compare two ways of taking atezolizumab (a cancer drug) in people with non-small cell lung cancer. The study will look at whether people prefer taking atezolizumab by injection under the skin or through a vein.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2019 Phase 3 trial • 1225 Patients • NCT02008227Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have had lung conditions like pulmonary fibrosis or pneumonitis.I have lung cancer that has spread to my brain and is causing symptoms or getting worse.My doctor believes I have at least 18 weeks to live.I have stage IV NSCLC and haven't received systemic treatment for it.I have or had an autoimmune disease or immune deficiency.I had surgery to remove early-stage lung cancer.I frequently need procedures to remove excess fluid from my body.I have cancer pain that is not relieved by treatment.My early-stage lung cancer shows some PD-L1 activity.My cancer has a specific genetic change in the EGFR gene or ALK gene.I haven't had cancer treatment for at least 6 months.I have high calcium levels in my blood that are causing symptoms.I am fully active or can carry out light work.I finished my early-stage lung cancer treatment 4-12 weeks ago and have recovered.My advanced lung cancer shows high PD-L1 levels.I have had cancer within the last 5 years, but it was either the type being studied now or one unlikely to spread.I have had leptomeningeal disease.My lung cancer is confirmed to be Stage IV, either non-squamous or squamous.I haven't had major heart issues or unstable chest pain in the last 3 months.
- Group 1: Treatment A
- Group 2: Treatment B
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the Atezolizumab drug's official status?
"Atezolizumab has not demonstrated efficacy in any clinical trials, however it has been shown to be safe in Phase 2 testing."
How many people fit the bill for this research project?
"The trial is still recruiting patients, as the information on clinicaltrials.gov indicates. 18 different hospitals are looking for a total of 140 individuals to enroll in the study. The study was first posted on April 4th, 2020 and updated November 15th, 2020."
Are new participants being accepted into this clinical trial at this time?
"The listing on clinicaltrials.gov indeed shows that this trial is ongoing and recruiting patients. It was originally posted on April 4th, 2022 and updated November 15th of the same year. The study needs 140 people in total, with 18 different locations advertising openings."
Is this study limited to North American medical facilities?
"There are a total of 18 locations enrolling patients for this study, which include Lancaster, Spokane, Salt Lake City and 15 other sites. To reduce travel burden, it is advisable to select the clinical site nearest you."
What was the outcome of earlier clinical trials that tested Atezolizumab?
"Atezolizumab's journey began in 2008 at Illinois Cancer Care. As of now, 356 active trials are being conducted and 79 have been completed. A significant amount of research is being performed out of Lancaster, South carolina."
Atezolizumab is most often used to treat which condition?
"Atezolizumab is most often taken to treat small cell lung cancer, but it can also be used as a treatment for malignant neoplasms, non-small cell lung carcinoma, and postoperative patients."
What are the precedents for this type of research?
"Atezolizumab is being tested in 356 different ongoing trials, located across 74 countries and 1665 cities. The first trial began in 2008, with 720 patients enrolled. This study completed Phase 2 drug approval stage, and since then 79 more studies have reached completion."
Share this study with friends
Copy Link
Messenger